Boston Scientific Corp. (NYSE:BSX) – Research analysts at Wedbush raised their FY2017 earnings per share estimates for Boston Scientific Corp. in a note issued to investors on Monday. Wedbush analyst Levy. T now expects that the brokerage will earn $1.28 per share for the year, up from their previous estimate of $1.25. Wedbush has a “Neutral” rating and a $25.00 price objective on the stock.

Several other research analysts also recently commented on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $28.00 price target on shares of Boston Scientific Corp. in a research note on Friday, October 14th. Citigroup Inc. raised their price target on shares of Boston Scientific Corp. from $28.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, October 6th. Zacks Investment Research raised shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research note on Tuesday, October 4th. Argus raised shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating and raised their target price for the company from $23.82 to $33.00 in a research report on Thursday, September 1st. They noted that the move was a valuation call. Finally, Evercore ISI reissued a “buy” rating and set a $26.00 target price (up previously from $25.50) on shares of Boston Scientific Corp. in a research report on Sunday, July 31st. Five research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $25.19.

Earnings History and Estimates for Boston Scientific Corp. (NYSE:BSX)

Shares of Boston Scientific Corp. (NYSE:BSX) traded down 0.17% on Tuesday, hitting $23.08. 1,864,744 shares of the stock traded hands. Boston Scientific Corp. has a 52-week low of $15.67 and a 52-week high of $24.79. The stock’s market cap is $31.41 billion. The stock’s 50 day moving average price is $23.62 and its 200 day moving average price is $22.79.

Boston Scientific Corp. (NYSE:BSX) last issued its earnings results on Thursday, July 28th. The company reported $0.27 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.27. The firm had revenue of $2.13 billion for the quarter, compared to the consensus estimate of $2.05 billion. Boston Scientific Corp. had a negative net margin of 4.34% and a positive return on equity of 22.66%. The business’s revenue was up 15.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.22 earnings per share.

Several institutional investors have recently bought and sold shares of BSX. JPMorgan Chase & Co. raised its position in Boston Scientific Corp. by 116.4% in the second quarter. JPMorgan Chase & Co. now owns 45,873,864 shares of the company’s stock valued at $1,072,070,000 after buying an additional 24,672,937 shares during the period. Wellington Management Group LLP raised its stake in shares of Boston Scientific Corp. by 9.1% in the first quarter. Wellington Management Group LLP now owns 103,378,526 shares of the company’s stock valued at $1,944,549,000 after buying an additional 8,643,058 shares during the last quarter. Eaton Vance Management raised its stake in shares of Boston Scientific Corp. by 14,198.2% in the second quarter. Eaton Vance Management now owns 3,907,561 shares of the company’s stock valued at $91,320,000 after buying an additional 3,880,232 shares during the last quarter. BlackRock Investment Management LLC raised its stake in shares of Boston Scientific Corp. by 98.3% in the second quarter. BlackRock Investment Management LLC now owns 7,165,917 shares of the company’s stock valued at $167,467,000 after buying an additional 3,552,349 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in shares of Boston Scientific Corp. by 1,748.3% in the second quarter. Marshall Wace LLP now owns 3,258,892 shares of the company’s stock valued at $76,159,000 after buying an additional 3,082,574 shares during the last quarter. 92.05% of the stock is owned by hedge funds and other institutional investors.

In other news, EVP Timothy A. Pratt sold 24,000 shares of Boston Scientific Corp. stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $24.46, for a total transaction of $587,040.00. Following the completion of the transaction, the executive vice president now directly owns 287,495 shares of the company’s stock, valued at approximately $7,032,127.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP John Bradley Sorenson sold 2,500 shares of Boston Scientific Corp. stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $23.90, for a total transaction of $59,750.00. Following the transaction, the senior vice president now directly owns 12,615 shares of the company’s stock, valued at $301,498.50. The disclosure for this sale can be found here. Insiders own 1.31% of the company’s stock.

About Boston Scientific Corp.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

5 Day Chart for NYSE:BSX

Receive News & Stock Ratings for Boston Scientific Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corp. and related stocks with our FREE daily email newsletter.